BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 31587306)

  • 1. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
    Carr AS; Pelayo-Negro AL; Jaunmuktane Z; Scalco RS; Hutt D; Evans MR; Heally E; Brandner S; Holton J; Blake J; Whelan CJ; Wechalekar AD; Gillmore JD; Hawkins PN; Reilly MM
    Neuromuscul Disord; 2015 Jun; 25(6):511-5. PubMed ID: 25819286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
    Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gait abnormalities in older adults with transthyretin cardiac amyloidosis.
    Petros FE; Santos AM; Adeniyi A; Teruya S; De Los Santos J; Maurer MS; Agrawal SK
    Amyloid; 2024 Jun; 31(2):116-123. PubMed ID: 38433466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromuscular Complications of Systemic Amyloidosis.
    Namiranian D; Geisler S
    Am J Med; 2022 Apr; 135 Suppl 1():S13-S19. PubMed ID: 35104443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
    Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
    Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
    Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
    Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic transthyretin amyloidosis in a patient with bent spine syndrome.
    Rezania K; Pytel P; Smit LJ; Mastrianni J; Dina MA; Highsmith WE; Dogan A
    Amyloid; 2013 Jun; 20(2):131-4. PubMed ID: 23638719
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Wlodarski R; Seibert K; Issa NP; O'Brien-Penney B; Soliven B; Sarswat N; Appelbaum D; Rezania K
    Muscle Nerve; 2023 Feb; 67(2):111-116. PubMed ID: 36222831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
    Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
    Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
    ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.